With its GLP-1 therapies Mounjaro and Zepbound, Eli Lilly has developed into one of the most important growth stocks in the healthcare sector. The company benefits from the globally increasing demand for obesity and diabetes treatments, strong revenue growth, rising margins, and a promising pipeline. Despite a high valuation and increasing competition, the long-term prospects remain attractive thanks to innovative strength, production expansion, and positive market sentiment.